|
Video: What is a Stock Split?
|
|
Petros Pharmaceuticals is a pharmaceutical company focused on men's health therapeutics with a range of capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. Co. is engaged in the commercialization and development of Stendra®, a PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). Co. also markets its own line of ED products in the form of vacuum erection device products. In addition to ED products, Co. has a license to develop and commercialize H100, a topical formulation candidate for the treatment of acute Peyronie's disease. According to our PTPI split history records, Petros Pharmaceuticals has had 1 split. | |
|
Petros Pharmaceuticals (PTPI) has 1 split in our PTPI split history database. The split for PTPI took place on December 01, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of PTPI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Petros Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PTPI split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Petros Pharmaceuticals shares, starting with a $10,000 purchase of PTPI, presented on a split-history-adjusted basis factoring in the complete PTPI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/03/2020 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$34.50 |
|
End price/share: |
$0.64 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.14% |
|
Average Annual Total Return: |
-69.11% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$185.43 |
|
Years: |
3.39 |
|
|
|
Date |
Ratio |
12/01/2022 | 1 for 10 |
|
|